Related Party Transactions	9 Months Ended
Sep. 30, 2020
Related Party Transactions [Abstract]
Related Party Transactions	14. Related Party Transactions In 2019, certain employees of Third Rock Ventures, a stockholder of the Company, provided consulting services to the Company. Commencing January 2020, Third Rock Ventures ceased providing management consulting services to the Company, The Company recorded no consulting expenses for consulting services provided by Third Rock Ventures during the three and nine months ended September 30, 2020. The Company recorded Third Rock Ventures consulting expenses to general and administrative expense of $6,000 and $32,000, respectively for the three and nine months ended September 30, 2019. In March 2020, the Company granted 26,573 stock options with a grant date fair value of $0.1 million to a partner at Third Rock Ventures, who is also serving as a non-employee director on the Company’s Board of Directors. The common shares subject to these options vest 1/12th on the last day of each calendar quarter over a three-year period and commenced vesting upon our IPO. Lastly, in order to vest at each calendar quarter end date, the shareholder must be providing continuous service to the Company through such vesting date. See Note 11 for additional information. From time to time, the Company makes charitable contributions to the University of California, San Francisco Foundation (the “UCSF Foundation”), which are directed to support research performed in the laboratories of two of the Company’s scientific founders. The Company made no charitable contributions to the UCSF Foundation during the three months ended September 30, 2020 and 2019. The Company made charitable contributions to the UCSF Foundation in the amount of $0.7 million and $0.4 million during the nine months ended September 30, 2020 and 2019, respectively. In October 2019, the Company entered into the Novartis Agreement with Novartis covering the development and commercialization of Pliant’s preclinical product candidate, PLN-1474 and up to three additional targets. Upon execution of the Agreement, Pliant also entered into a financing side letter with Novartis, whereby Novartis committed to provide up to $30.0 million in equity financing of which $20.0 million was provided for preferred shares as a part of a Series C equity offering and the remaining $10.0 million was completed in a private placement for common shares upon the Company’s IPO. As of September 30, 2020 and December 31, 2019, Novartis owned approximately 6.1% and 7.4 %, respectively, of our outstanding shares of common stock on a fully diluted basis. See Notes 6 and Note 9 for additional information.

Related Party Transactions

9 Months Ended

Sep. 30, 2020

14. Related Party Transactions

In 2019, certain employees of Third Rock Ventures, a stockholder of the Company, provided consulting services to the Company. Commencing January 2020, Third Rock Ventures ceased providing management consulting services to the Company, The Company recorded no consulting expenses for consulting services provided by Third Rock Ventures during the three and nine months ended September 30, 2020. The Company recorded Third Rock Ventures consulting expenses to general and administrative expense of $6,000 and $32,000, respectively for the three and nine months ended September 30, 2019.

In March 2020, the Company granted 26,573 stock options with a grant date fair value of $0.1 million to a partner at Third Rock Ventures, who is also serving as a non-employee director on the Company’s Board of Directors. The common shares subject to these options vest 1/12th on the last day of each calendar quarter over a three-year period and commenced vesting upon our IPO. Lastly, in order to vest at each calendar quarter end date, the shareholder must be providing continuous service to the Company through such vesting date. See Note 11 for additional information.

From time to time, the Company makes charitable contributions to the University of California, San Francisco Foundation (the “UCSF Foundation”), which are directed to support research performed in the laboratories of two of the Company’s scientific founders. The Company made no charitable contributions to the UCSF Foundation during the three months ended September 30, 2020 and 2019. The Company made charitable contributions to the UCSF Foundation in the amount of $0.7 million and $0.4 million during the nine months ended September 30, 2020 and 2019, respectively.

In October 2019, the Company entered into the Novartis Agreement with Novartis covering the development and commercialization of Pliant’s preclinical product candidate, PLN-1474 and up to three additional targets. Upon execution of the Agreement, Pliant also entered into a financing side letter with Novartis, whereby Novartis committed to provide up to $30.0 million in equity financing of which $20.0 million was provided for preferred shares as a part of a Series C equity offering and the remaining $10.0 million was completed in a private placement for common shares upon the Company’s IPO. As of September 30, 2020 and December 31, 2019, Novartis owned approximately 6.1% and 7.4 %, respectively, of our outstanding shares of common stock on a fully diluted basis. See Notes 6 and Note 9 for additional information.